Clinical Trial Update: Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating apatinib for EGFR T790M-negative non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Lung Diseases, Neoplasms | Phase 2 | Status: UNKNOWN